| Date | Price Target | Rating | Analyst |
|---|
8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
425 - Keen Vision Acquisition Corp. (0001889983) (Subject)
10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)
8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)
Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart's human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio's cloud-based Pulse™ analytics, enabling smart and accelerated cardiac drug screening.Industry-First Capabilities Combined: Medera's Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and FTD applications. As a pioneer in pre-clinical screening, Curi Bio has advanced cloud-based data analysis tools.Accelerated Drug Development: With newly introduced technologies, the combined platform is expected to increase e
Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing protocols, setting a new benchmark for human-based cardiac screeningLatest enhanced 96-well technology enables rapid, high-throughput screening on bioengineered human heart tissues, with significant cost and efficiency gains BOSTON and GOTHENBURG, Sweden, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, and Novoheart, its wholly owned pre-clinical sub
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costsHuman-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancementsThis new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platformInnovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per yearHeart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeuticsPromising efficacy results in cardiovascular performance observed in Cohort A (low-dose SRD-002) at six months with additional data being collectedInitiated dosing patients in Cohort B (high-dose SRD-002) following recommendation of the DSMBSUMMIT, N.J. and BOSTON, Oct. 24, 2024 /PRNewswire/ -- Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-
SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)
SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)
SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)
SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)